title: [Significance of bortezomib and dexamethasone therapy for multiple myeloma showing a serum creatinine level above 2 mg/dl].
abstract: Here, we retrospectively assessed the reversibility of renal impairment and anti-myeloma effect of bortezomib and dexamethasone (BD therapy) for Japanese patients with multiple myeloma showing a serum creatinine level above 2 mg/dl. Improvement of renal impairment was observed in 6 of 7 patients following a median of 2.4 cycles of BD therapy. Three of 7 patients achieved more than partial response by BD therapy. The present study demonstrated that BD therapy was highly effective for the treatment of Japanese myeloma patients with renal impairment.
authors.affiliation: Division of Hematology, National Hospital Organization Disaster Medical Center.
authors.forename: Naohiro
authors.initials: N
authors.lastname: Sekiguchi
authors.forename: Naoki
authors.initials: N
authors.lastname: Takezako
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Haga
authors.forename: Akihisa
authors.initials: A
authors.lastname: Nagata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Noto
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Miwa
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D003404:Creatinine / Q000097:blood*; D003907:Dexamethasone / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D003404:Creatinine